Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Decitabine + Tirelizumab in Advanced ESCC
NCT05638984Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Jan 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of decitabine in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Fudan University. Primary endpoint: Progression-Free Survival. Status: unknown.
02
Drugs
decitabine
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05638984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05638984.